Company intelligence / Profile preview

Yeda Research and Development

Rehovot, Israel

Ownership: Private
Employees: ~33
Development stage: Other

Overview

Yeda focuses on commercializing research from the Weizmann Institute of Science. Recent achievements include a breakthrough discovery in cancer immunotherapy: an antibody treatment that blocks CD84-mediated molecular bridges in the tumor microenvironment, which showed promise in triple-negative breast cancer and blood cancers by restoring immune system attack on cancer cells. This technology was commercialized through Slam BioTherapeutics, a joint venture with City of Hope.[1]

Therapeutic areas: OncologyHematology
Modalities: AntibodyMonoclonal antibodyGene therapyCell therapySmall moleculeProteinVaccine
Industry: Academic Hospital/University/Research

Partnerships

City of HopeWeizmann Institute of ScienceCoImmune, Inc.

Beyond the preview

Go deeper on Yeda Research and Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yeda Research and Development.

Explore the full profile